VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

Other equities analysts also recently issued reports about the stock. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Thursday, February 6th.

VolitionRx Trading Down 3.8 %

NYSE:VNRX opened at $0.61 on Friday. The company’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.65. The company has a market cap of $56.16 million, a P/E ratio of -1.68 and a beta of 1.20. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.10.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds bought 139,811 shares of VolitionRx stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 358,266 shares of company stock valued at $204,212 over the last ninety days. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Institutional investors have recently made changes to their positions in the stock. Ground Swell Capital LLC increased its position in shares of VolitionRx by 78.8% during the third quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock valued at $28,000 after acquiring an additional 20,249 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of VolitionRx during the fourth quarter valued at about $29,000. Millennium Management LLC acquired a new stake in shares of VolitionRx during the fourth quarter valued at about $36,000. Northern Trust Corp increased its position in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.